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Melanomas are highly heterogeneous tumors, but
the biological significance of their different subpopu-
lations is not clear. Using the H3K4 demethylase
JARID1B (KDM5B/PLU-1/RBP2-H1) as a biomarker,
we have characterized a small subpopulation of
slow-cycling melanoma cells that cycle with
doubling times of >4 weeks within the rapidly prolif-
erating main population. Isolated JARID1B-positive
melanoma cells give rise to a highly proliferative
progeny. Knockdown of JARID1B leads to an initial
acceleration of tumor growth followed by exhaustion
which suggests that the JARID1B-positive subpopu-
lation is essential for continuous tumor growth.
Expression of JARID1B is dynamically regulated
and does not follow a hierarchical cancer stem cell
model because JARID1B-negative cells can become
positive and even single melanoma cells irrespective
of selection are tumorigenic. These results suggest
a new understanding of melanoma heterogeneity
with tumor maintenance as a dynamic process medi-
ated by a temporarily distinct subpopulation.
INTRODUCTION
Malignant melanoma is an aggressive tumor of neuroectodermal
origin that can be cured if excised in an early stage, however,
once disseminated to distant organs, the median survival of
melanoma patients drops below 9 months (Gogas et al., 2007).
The vast intratumoral heterogeneity of melanoma paired with
the potential for continuous tumor self-renewal previously led
to the question of whether melanomas follow the cancer stem
cell (CSC) model with a melanoma stem cell on top of a tumor
differentiation pyramid (Reya et al., 2001; Zabierowski and Her-
lyn, 2008). Since the initial validation of the CSC model for acutemyeloid leukemia (Bonnet and Dick, 1997), CSCs have been
identified in various solid tumors, e.g., breast (Wright et al.,
2008) or brain cancer (Singh et al., 2003). We previously reported
that the B cell marker CD20 is indicative for self-renewal of mela-
noma spheres after propagation in stem cell medium (Fang et al.,
2005). Subsequently, other markers, e.g., CD133 (Monzani et al.,
2007) or ABCB5 (Schatton et al., 2008), have been used to
characterize stem-like subpopulations in melanomas with
frequencies broadly ranging between 0.0001% and 0.1% of
the total population depending on the (surface) marker and
experimental methods used. However, a recent seminal publica-
tion pointed out that modifications to xenotransplantation
assays, which currently represent the standard assay to assess
tumor self-renewal (Clarke et al., 2006), can dramatically
increase the frequency of tumor-initiating/melanoma stem cells
up to 25% of unsorted cells, i.e., independent from any putative
marker (Quintana et al., 2008). Besides the conclusion that basi-
cally every melanoma cell could initiate a tumor if the host
system is susceptible enough, this new finding refreshed the
ongoing discussion about suitable experimental models, the
definition, and, finally, the existence of melanoma stem cells
(Adams and Strasser, 2008). Melanomas may not be hierarchi-
cally organized into subpopulations of tumorigenic and nontu-
morigenic cells and the CSC model might not account for mela-
noma heterogeneity. However, it remains unanswered if, within
an established tumor microenvironment, continuous tumor
maintenance is similarly assured by each individual melanoma
cell or if distinct subpopulations are more suited as a resource
for replenishment. In the latter scenario, the potential to continu-
ously maintain tumors might be independent of the capacity to
initiate new tumors in host organisms and might not follow
a unidirectional CSC model, particularly when the considerable
plasticity and heterogeneity of melanomas are taken into consid-
eration.
JARID1B (KDM5B/PLU-1/RBP2-H1, Lu et al., 1999; Roesch
et al., 2005; Vogt et al., 1999) is a member of the highly con-
served family of jumonji/ARID1 (JARID1) histone 3 K4 (H3K4)
demethylases which are involved in tissue development, cancer,Cell 141, 583–594, May 14, 2010 ª2010 Elsevier Inc. 583
Figure 1. Melanomas Contain a Subpopula-
tion of Slow-Cycling Cells Characterized by
Increased JARID1B Expression
(A) Left panel: Representative example of a vertical
growth phase melanoma after immunostaining for
JARID1B. Single positive cells (arrows) with
predominantly nuclear and minor cytoplasmic
staining are surrounded by negative cells. Middle:
Single adherent WM3734 melanoma cells show
high JARID1B (arrows) while the bulk of cells
shows median or low expression (arrowheads)
when grown in conventional medium (Tu2%).
Isotype control (top) and higher magnification
(bottom) are shown as inserts. Right: More distinct
JARID1B staining was seen in cryosections of
WM3734 melanoma spheres (hESCM4). Digital
quantitation after pseudocoloring revealed a rela-
tive frequency of 4% JARID1B-immunopositive
(green) and 96% immunonegative cells (blue) for
this section (see also Figure S1).
(B) Anti- JARID1B-positive cells (Alexa Fluor 488,
green) are predominately negative for the prolifer-
ation marker Ki-67 (Alexa Fluor 568, red). The
result was reproduced in WM115 cells (not
shown).
(C) Flow cytometry analysis ofWM3734melanoma
sphere cells after incubation with PKH26 (black
line) compared to unlabeled control cells (gray
line). After 4 weeks in hESCM4, 2% of the cells
retained the maximum label (label-retaining ‘LR’
cells, white square).
(D) LR cells displayed significantly enhanced
JARID1B expression compared to nonlabel-
retaining (nLR) cells in QPCR. (E) QPCR screening
of side population cells from WM3734 and WM35
melanoma sphere cells showing an upregulation
of JARID1B compared to the main populations.
Error bars represent the SD.and normal stem cell biology (Christensen et al., 2007; Iwase
et al., 2007; Klose et al., 2007; Yamane et al., 2007). In normal
adult tissues, JARID1B is marginally expressed with dramatic
peak expression levels in regenerative tissues like testis and
bone marrow (Roesch et al., 2005; Vogt et al., 1999). In cancer,
JARID1B functions as a transcriptional regulator of oncogenes,
e.g., BRCA1 in breast cancer, via direct interaction with
promoter sites (Scibetta et al., 2007; Tan et al., 2003). Depending
on the cancer context, JARID1B is associated with either posi-
tive (melanoma) or negative (breast cancer) cell cycle control
(Roesch et al., 2006, 2008; Scibetta et al., 2007; Yamane et al.,
2007). In melanocytic tumors, JARID1B is highly expressed in
benign nevi, which typically are characterized by oncogene-
induced senescence. However, in aggressive primary mela-
nomas and melanoma metastases, there are only single cells
with high JARID1B expression (5%–10% of the total popula-
tion, [Roesch et al., 2005]).
Given JARID1B’s potential role in stem cell biology and the
low percentage of melanoma cells expressing JARID1B within
the bulk population, we asked, (1) if the JARID1B-positive584 Cell 141, 583–594, May 14, 2010 ª2010 Elsevier Inc.subpopulation has an enhanced potential for maintenance of
the entire tumor, and (2) if/how this subpopulation differs from
the current definition of aCSC.Our findings argue against a unidi-
rectional CSC model in melanomas leading to an alternative
concept of tumor heterogeneity with dynamic subpopulations
of tumor-maintaining cells.
RESULTS
Identification of JARID1B as a Marker for Slow-Cycling
Melanoma Cells
JARID1B is highly expressed in a small percentage of melanoma
cells in advanced patients’ tumors (Roesch et al., 2005); a repre-
sentative example is shown in Figure 1A. Similar expression can
be observed in melanoma cell lines. Independent of the cell line
analyzed, immunostaining showed broad ‘‘intraculture’’ hetero-
geneity of JARID1B. Under conventional culture conditions,
some cells expressed high levels of JARID1B while most ex-
pressed medium to low levels (Figure 1 A). In contrast, human
embryonic stem cell medium (hESCM4)-derived melanoma
Figure 2. JARID1B Is aBiomarker for theLa-
bel-Retaining Subpopulation in Melanoma
(A) Lentiviral pLU-JARID1Bprom-EGFP-Blast.
(B) Flow cytometric determination of the J/EGFP-
positive subpopulation, exemplarily shown for
WM3734JARID1Bprom-EGFP melanoma spheres
grown in hESCM4 (see also Figure S2). QPCR
and immunoblots of sorted populations showed
a significant correlation between exogenous
EGFP and endogenous JARID1B expression
(p < 0.05, t test). The 5%-threshold was based
on our in vitro and in vivo observations on endog-
enous JARID1B expression frequency (Figure 1).
(C)PKH26 label-retentionofWM3734JARID1Bprom-EGFP
sphere cells in vitro. Left: LR cells grouped as
a distinct J/EGFP-positive subpopulation (LR/
JEGFP-positive, white square) and were enriched
for small-sized cells. Right: LR-J/EGFP-positive
cells (white bar) showed the highest capacity to
reform spheres. Depicted is one representative
out of three independent experiments.
(D) Left: Anti-BrdU-APC flow cytometry of dissoci-
ated tumor cells revealed that 6 weeks after BrdU
incubation the majority of cells diluted out the
BrdU (filled black). Unlabeled (gray line) and freshly
BrdU-labeled cells (black line) served as controls.
The threshold was set to the peak APC intensity
of freshly BrdU-labeled cells. Right: In vivo BrdU-
labeled cells grouped as a distinct J/EGFP-posi-
tive subpopulation (LR/JEGFP-positive, white
square, 1.6% of total population).
Error bars represent the SD.spheres displayed a more distinct JARID1B heterogeneity, i.e.,
small-sized highly JARID1B-positive cells being surrounded
by a JARID1B-negative bulk population. Using digital quantita-
tion of pseudocolored immunosections, an average of 4.8%
JARID1B-positive cells was present across randomly selected
sphere sections (ten representative images out of five different
melanoma cell lines; Figure 1A and Figure S1A available online).
This pattern was similar to that observed in patients’ tumors
suggesting that growth as spheres in hESCM4 better recapitu-
lates the phenotype observed in vivo. Notably, JARID1B-positive
cells mostly lacked expression of the proliferation marker Ki-67
in both cultured cells and patient tumors (Figure 1B, Figure S1B),
suggesting a correlation between slow proliferation and
JARID1B expression.
To further explore a possible connection between JARID1B
and slow-cycling cells we used retention of the membrane dye
PKH26 as a marker for melanoma cells with a low doubling
rate. The sphere model was chosen because hESCM4 better
separates the JARID1B-positve subpopulation from the bulk.
The average doubling time of unsorted WM3734 cells is 48 hr.
Only 2%ofWM3734 cells retained themaximum amount of label
after 4 weeks suggesting that those cells had not divided
(Figure 1C). When assessed for JARID1B, PKH26 label-retaining
cells expressed higher levels than nonlabel-retaining bulk cells
(p < 0.05, t test, Figure 1D). Following the observation that
slow-cycling tumor cells show increased Hoechst 33342 efflux(Goodell et al., 1996), we applied side population analysis to
WM3734 and WM35 spheres. Subsequent QPCR revealed
a significant upregulation of JARID1B in side population cells
(Figure 1E, p < 0.05, t test). Genome-wide expression profiling
of label-retaining and side population cells from WM3734,
WM1976, WM115, and WM 3248 melanoma cell lines (data not
shown) suggested that other jumonji family members, e.g.,
JMJD1A, could be also differentially regulated; however, the
regulation of JARID1B appeared most consistent. Our data
indicate that even within highly proliferative melanomas, a JAR-
ID1B-positive subpopulation resides in a slow-cycling state and
melanoma heterogeneity might also apply to the level of cell
proliferation.
Slow-Cycling Melanoma Cells Form a Distinct
JARID1B-Positive Subpopulation In Vitro and In Vivo
For isolation of live JARID1B-positive cells, we cloned a lentiviral
construct, pLU-JARID1Bprom-EGFP-Blast, which drives cyto-
plasmic EGFP expression controlled by the co-cloned
human JARID1B promoter (abbreviated J/EGFP; Figures 2A
and 2B; Figure S2). When we analyzed stably infected
WM3734JARID1Bprom-EGFP melanoma cells that had been prela-
beled with PKH26 four weeks prior, the PKH26 label-retaining
cell population displayed as a distinct, almost completely
J/EGFP-positive subpopulation (Figure 2C). This population
was enriched for small-sized cells as reported to be typical forCell 141, 583–594, May 14, 2010 ª2010 Elsevier Inc. 585
melanoma cells with increased stemness (Grichnik et al., 2006).
Limited (single cell) dilution assays in hESCM4, which requires
self-renewal for continuous expansion as spheres (Fang et al.,
2005), revealed significantly increased sphere formation capacity
of the label-retaining-J/EGFP-doublepositivesubpopulationafter
21 days (Figure 2C, p = 0.0025, Fisher’s exact test). Of note, non-
label-retaining but J/EGFP-positive cells also self-renewed into
spheres, a finding which could be explained by the dynamics of
the JARID1B phenotype, as shown later (see Figure 6). Most of
the nonlabel-retaining-J/EGFP-negative cells died after 3 weeks
of culture in hESCM4. To exclude delayed sphere formation, the
plates were periodically reassessed (additional 3 weeks, not
shown). We next xenotransplanted WM3734JARID1Bprom-EGFP
melanoma cells into NOD/LtSscidIL2Rgnull mice and labeled the
developing tumors with intraperitoneally and orally administered
BrdU for 12 days (n = 5). After an additional 6 weeks of tumor
growth and BrdU dilution into subsequent daughter cells, BrdU
label-retaining-J/EGFP-positive cells were identified as a distinct
subpopulation and at a similar percentage (1%–2%) as seen
before in vitro (Figure 2D and Figure 1C).
The Slow-Cycling JARID1B-Positive Subpopulation
Shows Increased In Vitro Self-Renewal
As illustrated in Figure 3A, WM3734JARID1Bprom-EGFP melanoma
spheres were dissociated and sorted according to J/EGFP-
expression levels. Twenty-four hours after sorting, microscopic
evaluation showed similar numbers of healthy appearing single
cells in both populations. Low BrdU incorporation confirmed
that isolated J/EGFP-positive cells remained in a slow-cycling
state (Figure 3B, p < 0.05, t test). Slow-cycling cells incorporate
less BrdU compared to bulk cells but once incorporated
they retain it longer as shown in Figure 2. No significant differ-
ence in proliferation was observed between J/EGFP-positive
and -negative cells within the first days after sorting and reseed-
ing in hESCM4 (Figure 3C and Figure S3A). However, after day
10, there was a significant boost in the J/EGFP-positive-derived
progeny (p < 0.05, ANOVA). Interestingly, under conventional
culture conditions, the difference in proliferation was less distinct
(Figure S3B). Seven days after sorting, J/EGFP-positive
cells started to resemble the original culture heterogeneity of
J/EGFP-positive and -negative cells (Figure 3D). The enhanced
capacity of J/EGFP-positive cells to expand and to formahetero-
geneous progeny was confirmed by clonogenic assays in which
sorted cells were seeded at clonal density and grown for 21 days
in hESCM4 (Figure 3E, p < 0.01, t test). J/EGFP-positive sphere
cells also formed more and larger colonies in soft agar than
J/EGFP-negative cells (Figure 3F, p < 0.001, t test), indicating
increased anchorage-independent growth. Interestingly,
J/EGFP-negative cells formed the first visible colonies, but after
1–2 weeks growth exhausted, whereas colonies derived from
J/EGFP-positive cells accelerated growth. Finally, J/EGFP-posi-
tive cells reformed more spheres in single cell dilution assays
additionally suggesting increased self-renewal capacity (Fig-
ure 3G, p = 0.013, Fisher’s exact test). Single J/EGFP-negative
cells died or did not form spheres.
Together with the expression studies in melanoma patient
specimens and cell lines (Figure 1 and Figure S1), our data
suggest a JARID1B-expressing subpopulation that remains in a586 Cell 141, 583–594, May 14, 2010 ª2010 Elsevier Inc.slow-cycling state, butwhen released from itsmicroenvironment,
it can give rise to a rapidly proliferating progeny that reconstitutes
the parental heterogeneity of JARID1B-positive and -negative
cells. Particularly when the culture conditions supported the
survival of cells with inherent self-renewal potential (hESCM4),
single-seeded J/EGFP-positive cells were superior to single
J/EGFP-negative cells regarding their capacity to repopulate.
The JARID1B-Positive Phenotype Is Not a Prerequisite
for Tumor Initiation In Vivo
Titrated xenotransplantation assays were done in NOD/LtSsci-
dIL2Rgnull mice according to the improved protocol published
recently (Quintana et al., 2008). We subcutaneously injected
100, 10, or 1 cell from the FACS-isolated J/EGFP-positive
versus -negative subpopulation cultured in conventional
medium (each n = 20, Figure 3H). Unsorted cells were injected
as controls. The absolute tumor initiation rate of J/EGFP-positive
and -negative cells was nearly identical in line with the observa-
tions made by Quintana et al. We found in all titration steps that
J/EGFP-negative cells started to grow earlier. Although not
a statistically significant difference, this is consistent with our
in vitro observations of colony formation assays.
Knockdown of JARID1B Leads to In Vitro Exhaustion
of Melanoma Cells
Given the paradox of an increased in vitro self-renewal capacity
without any effect on in vivo tumor initiation, we asked whether
JARID1B could still be important for the continuous growth of
melanomas. JARID1B may not be required for tumor initiation
but in the maintenance of established tumors thus reflecting
two different biological processes. To address this, JARID1B
was stably knocked down in WM3734, WM35, and WM3899
melanoma cells (Figure 4) and in primary foreskin melanocytes
(FOM) as control (Figures S4H–S4J). JARID1B knockdown
efficiency was validated as summarized in Figure S4A–F. Two
shRNA clones targeting different mRNA regions of JARID1B
were selected for analysis. Off target effects were excluded by
computerized analysis (http://rnai.cs.unm.edu/offTarget). Un-
specific effects due to knockdown or secondary regulation of
other jumonji/ARID family members were excluded by cDNA
microarrays (data not shown). As expected from our previous
data on JARID1B-mediated cell cycle arrest (Roesch et al.,
2006), JARID1Bknockdownwas followedbyan increase inprolif-
erationstartingonday7after infection.However, afterday10, cell
proliferation flattened although the cells were still subconfluent
(Figure 4A and Figures S4D and S4E, p < 0.05, ANOVA). This
effect seemed to occur independently of the biological and
genetic backgrounds of the cell lines (Extended Experimental
Procedures). Knockdown of different JARID1B mRNA regions
showed similar results. Proliferation and pigmentation of normal
melanocytes, on theother hand, remainedunaffected (FigureS4).
After changing the culture conditions toward hESCM4, control
cells still formed viable spheres within 21 days, whereas knock-
down of JARID1B led to exhaustion after 28 (WM3899), 37
(WM3734), and 39 (WM35) days, respectively, with 86%–95%
cell death suggesting that in JARID1B knockdown cultures the
capacity for continuous growth was lost (Figure 4B). Cell exhaust
was confirmed for JARID1B knocked-down WM3928MP
Figure 3. In Vitro Self Renewal Capacity of the JARID1B-Positive Subpopulation
(A) Methodical scheme.
(B) Decreased BrdU incorporation into J/EGFP-positive cells 24 hr after separation from spheres (hESCM4) as determined by ELISA after pulsed BrdU exposition.
(C and D) (C) MTS assays of sorted J/EGFP-positive and –negative cells in hESCM4 (see also Figure S3). After day 10, the progeny of J/EGFP-positive cells
proliferated significantly faster and (D) microscopically consisted of J/EGFP-positive and an increasing number of J/EGFP-negative cells.
(E) Enhanced clonogenicity of single J/EGFP-positive cells.
(F and G) (F) J/EGFP-positive cells had both a higher potential to form 3D-colonies in 0.35% hESCM4-soft agar and (G) to self-renew again into heterogeneous
melanoma spheres in limited dilution assays (hESCM4). Shown are representative results from at least two independent experiments.
(H) Xenotransplantation growth curves after subcutaneous injection of 100, 10 or 1 WM3734JARID1Bprom-EGFP melanoma cell into NOD/LtSscidIL2Rgnull mice.
Growth curves were stopped when the first mouse of the respective series exceeded a tumor size > 1000 mm. Also during the subsequent observation of
remaining mice, no differences were seen.
Error bars represent the SD.
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Figure 4. In Vitro Exhaustion after Knockdown of JARID1B
(A) MTS proliferation assays between days 7–10 and days 30–33 after JARID1B knock down (clones 58 and 62, see also Figure S4). Experiments were done in
three independent approaches in conventional medium (Tu2%).
(B) Exposure of JARID1B knocked down cells (53 104 cells) to hESCM4 resulted in a strong increase of the number of trypan blue-positive cells after 4–6 weeks.
(C) Limited (single cell) dilution assays determined the reduction of melanoma sphere formation in JARID1B knockdown cells (right panel). The left panel shows
the corresponding cell morphologies.
(D) Reduced 3D colony formation after JARID1B knockdown in Tu2% softagar. Depicted are representative results from at least three independent experiments.
Error bars represent the SD.primary melanoma cells (Figures S4K and S4L). Furthermore,
30 days after seeding single cells in 96-well plates in hESCM4,
the decrease in sphere formation of WM3734 and WM3899
JARID1B knockdown cells could be quantified (Figure 4C, p <
0.05, Fisher’s exact test). Together with the observation that
spheres were predominantly generated from J/EGFP-positive
cells (Figure S2A, III) this indicates that JARID1B defines a
subpopulation which is involved in self-renewal of spheres. As
seen with J/EGFP-negative cells (Figure 3F), JARID1B knock-
down lines also formed fewer soft agar colonies after 2–3 weeks
(Figure 4D, p < 0.001 and p < 0.01, t test).588 Cell 141, 583–594, May 14, 2010 ª2010 Elsevier Inc.JARID1B Is Required for Continuous Growth of
Xenografted Melanoma and for Metastatic Progression
Serial xenotransplantation assays allow assessment of long-
term growth of implanted tumor cells without temporary restric-
tions due to maximum tumor size (Clarke et al., 2006) and,
therefore, were applied to investigate the influence of JARID1B
knockdown on in vivo tumor growth. In the first passage, there
was higher proliferation rate of JARID1B knockdown cells
compared to the control (Figure 5A, p < 0.05, ANOVA) which
mimicked the proliferation pattern seen in vitro (Figure 4A) and
the results from single injected J/EGFP-negative cells
Figure 5. In Vivo Exhaustion after Knock-
down of JARID1B
(A) In vivo tumor growth is exhausted after 4
passages of serial xenotransplantation of JAR-
ID1B knockdown WM3734 cells in NOD/LtSsci-
dIL2Rgnull mice (n = 5 per sample) compared to
the control (see also Figure S5).
(B) Normalized growth ratio (tumor volumes of sh
JARID1B tumors divided by volumes of sh scram-
bled tumors) over the cumulative growth phase of
27 weeks.
(C) Significant decrease of pulmonary metastasis
after subcutaneous injection of 5 3 105 JARID1B
knocked down WM3899 cells into NOD/LtSsci-
dIL2Rgnull mice (n = 5 per sample). Shown is one
representative from two independent experi-
ments.
Error bars represent the SD.(Figure 3H). Strikingly, in the subsequent three in vivo passages
(Figure 5A and Figure S5), JARID1B knockdown cells gradually
lost their potential to expand (p < 0.05, ANOVA). When tumor
growth was displayed as a relative ratio normalized to the sh
scrambled control (Figure 5B), it became apparent that over
the total incubation time of 27 weeks in vivo, the proliferation
of JARID1B knockdown cells peaked and then steadily ex-
hausted as predicted by our in vitro experiments. Using
WM3899 cells, which are known to spontaneously metastasize
to the lungs after subcutaneous xenotransplantation, we found
a reduction of metastases by JARID1B knockdown cells, as
determined by computerized quantitation of histological
sections (Figure 5C, p < 0.05, t test). The process of continuous
tumor maintenance can only be seen in long-term experiments
and seems to be independent of the initial tumor formation.
The JARID1B Phenotype Is Dynamic
The CSC concept postulates a unidirectional hierarchy of tumor
cells (Reya et al., 2001). Long-term culture after FACS indeed
confirmed that the J/EGFP-positive subpopulation induces a
heterogeneous daughter population consisting of J/EGFP-
positive and –negative cells. Fourteen days after FACS and
reseeding in conventional medium, the J/EGFP-positive-derived
progeny consisted of J/EGFP-positive cells and an increasing
number of J/EGFP-negative cells (Figure 6A, III). Development
of a heterogeneous tumor population was also seen in vivo
56 days after J/EGFP-positive cells (100, 10, or 1) had been
xenotransplanted (Figure 6A, V). However, after 14 days in vitro
or 56 days in vivo, also J/EGFP-negative cells gave rise to a
heterogeneous progeny including J/EGFP-positive cells (Fig-
ure 6A, IV and VI), even when derived from a single J/EGFP-
negative cell. The re-establishing culture heterogeneity in both
progenies resulted in a balanced overall JARID1B expression
(Figure 6C). When sorted cells were cultured in hESCM4 ratherCell 141, 583–5than conventional medium, the intercon-
version of phenotypes was considerably
decelerated (Figure 6A, VII and VIII).
Even after 120 days, only a few J/EGFP-
positive cells were found in cultures
derived from J/EGFP-negative cells(Figure 6A, VII andB). Accordingly, J/EGFP-positive cells seeded
in hESCM4 maintained a higher number of J/EGFP-positive
cells. Daughter cultures from both J/EGFP-positive or –negative
cells could be cultured for several months without exhaustion
which suggests that the self renewal function of second genera-
tion J/EGFP-positive cells is also reversible.
Since conventional culture conditions seemed to allow a
higher dynamics of the JARID1B-positive phenotype, we
repeated clonogenic and colony formation assays of sorted cells
in conventional medium. Although J/EGFP-positive cells still
showed increased colony formation, now the difference from
J/EGFP-negative cells was clearly decreased compared to
hESCM4 (Figures S3C and S3D versus Figure 3). Next to soluble
factors from the culture medium, we identified oxygen as sig-
nificant environmental factor for the dynamic regulation of JAR-
ID1B (Figure S6). In agreement with a recent report in HepG2
hepatocellular carcinoma and U87 glioblastoma-astrocytoma
cells (Xia et al., 2009), JARID1B expression in melanoma cells
rapidly enhanced at low oxygen (3 days, 1% pO2) and steadily
reverted to normal expression intensity and frequency after 10
to 14 days of conventional culture at atmospheric oxygen. At
last, we observed that J/EGFP-negative cells that were grown
as dense patches usually developed a more distinct J/EGFP-
positive subpopulation than J/EGFP-negative cells that were
kept at lower density (data not shown). Finally, the dynamics of
the JARID1B phenotype also explains the relatively high sphere
forming capacity of nonlabel-retaining but J/EGFP-positive cells
(shown in Figure 2C). These cells most likely acquired the
J/EGFP-associated self-renewal potential after PKH-labeling.
JARID1B Affects Jagged 1/Notch 1-Signaling
in Melanoma Cells
The bidirectional Notch signaling pathway is known to maintain
neural progenitors and melanocyte stem cells (Moriyama et al.,94, May 14, 2010 ª2010 Elsevier Inc. 589
Figure 6. The JARID1B Phenotype Is Dynamic
(A) WM3734JARID1Bprom-EGFP cells were sorted according to J/EGFP levels as described before using maximum and minimum thresholds set at 5%. Untreated
parental cells were used as a background control (gray line). Panel I: typical histogram presort in conventional medium (Tu2%). Panel II: isolated J/EGFP-positive
(filled black) and J/EGFP-negative cells (black line) 6 hr after FACS. Panel III: during subsequent culturing in Tu2% medium, the J/EGFP-positive subpopulation
re-established a heterogeneous progeny of J/EGFP-positive and -negative cells (filled black). Panel V: same result in vivo after injection into NOD/LtSscidIL2Rgnull
mice (filled black). Panels IV and VI: also J/EGFP-negative cells gave rise to a heterogeneous progeny including J/EGFP-positive cells (black line). Panel VII: in
hESCM4, the J/EGFP-positive-derived progenymaintained a high number of J/EGFP-positive cells (filled black). Panel VIII: also the reversion of J/EGFP-negative
to -positive cells was considerably decelerated (50 day line dashed, 120 day line black). Black and white arrowheads indicate developing positive and negative
subpopulations. Depicted tumor histograms resulted from injection of 100 J/EGFP-positive or -negative cells into NOD/LtSscidIL2Rgnull mice (abbreviated NOD/
SCID). Shown are representative histograms from at least three analyses.
(B) Immunofluorescence of cultures originating from J/EGFP-positive (left) and J/EGFP-negative cells (right) after 120 days in hESCM4.
(C) Similar overall JARID1Bexpression in J/EGFP-positive and -negative-derivedprogenies after long-termculturing asdeterminedbyQPCRand immunoblotting.
See also Figure S6.
Error bars represent the SD.
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Figure 7. JARID1B Affects Jagged 1/Notch
1 Signaling
(A) QPCR of A375-SM melanoma cells transiently
transfected with pBIND-JARID1B versus empty
vector control (upper panel) and of JARID1B-
knocked down WM3734, WM35, and WM3899
cells versus sh scrambled control (lower panel).
(B) Immunoblotting of JARID1B-transfected
A375-SM melanoma and HEK293 control cells
with antibodies against JAG1, uncleaved and
cleaved Notch 1. Notch cleavage was confirmed
by a second antibody.
(C) Differential JAG1 expression and Notch cleav-
age in FACS-isolated J/EGFP-positive and -nega-
tive cells.
(D) Differential expression of HEY1 and 2 in
J/EGFP-positive and -negative cells.
Error bars represent the SD.2006) and, as we reported earlier, also propagates melanoma
progression (Balint et al., 2005; Liu et al., 2006; Pinnix et al.,
2009). Besides, we showed that JARID1B transcriptionally
represses the Notch ligand Jagged 1 (JAG1) through direct
interaction with its promoter (Roesch et al., 2008). In low
JARID1B expressing A375-SM melanoma cells (Roesch et al.,
2005), transient transfection with JARID1B leads to a concen-
tration-dependent downregulation of JAG1, whereas stable
knock down in highly JARID1B-expressing WM3734 and
WM35 melanoma cells is followed by JAG1 upregulation
(Figures 7A and 7B). The JARID1B-mediated repression of
JAG1 in A375-SM cells was followed by reduced cleavage of
Notch 1 into its active form, Nic, while leaving the overall
expression of Notch 1 unchanged (Figure 7B). Notch cleavage
in nonmelanocytic control cells, HEK293, was not affected by
JARID1B (Figure 7B). Since in experimentally ‘‘homogenized’’
cultures (by transfection or lentiviral infection), the bidirectional
nature of Notch signaling could be masked, we next switched
to endogenously JARID1B-positive versus –negative cells (J/
EGFP FACS). Again, high JARID1B expression was associated
with low JAG1, in both adherent and sphere cultures
(Figure 7C). Particularly in spheres, high JARID1B/low JAG1
was associated with high HEY1 and HEY2 expression, whichCell 141, 583–5are both common Notch downstream
targets (Figure 7D, p < 0.05, t test).
The inverse expression of JARID1B,
JAG1, and HEY1/2 among neighboring
cells is reminiscent of the concept of
lateral inhibition where reciprocal stimu-
lation/inhibition of Notch signaling dy-
namically leads to the maintenance of
neuroectodermal stem cells (Kageyama
et al., 2008). During differentiation of
neuroprogenitors, Nic levels were re-
ported to oscillate resulting in a steadily
increasing and decreasing activation of
downstream targets (Kageyama et al.,
2009). Thus, we suggest that togeth-
er with JAG1/Notch 1, JARID1B ispart of a complex dynamic program of stemness regulation in
melanoma.
DISCUSSION
JARID1B has recently been identified as a H3K4 demethylase
(Christensen et al., 2007; Yamane et al., 2007). H3K4methylation
has been proposed as a critical component in regulating gene
expression and cellular identities and as an epigenetic mark in
embryonic stem cells (Guenther et al., 2007). Demethylation of
H3K4 by JARID1B was shown to play a role in cell fate decisions
of embryonic stem cells by blockage of terminal differentiation
(Dey et al., 2008). In cancer, it is known that demethylation of
H3K4 supports transformation from hematopoietic precursors
to leukemia stem cells via regulation of the developmental Hox
gene family (Krivtsov and Armstrong, 2007). As previously sug-
gested for other chromatin remodeling factors such as HDACs
or the histone methylase SUV39H1 (Macaluso et al., 2006),
also JARID1B maybe part of a multi-molecular complex consist-
ing of DNA, histones, transcription factors such as PAX9,
FOXG1B, or LMO2, and pRB (Roesch et al., 2008; Tan et al.,
2003). Former studies by us indicated that JARID1B can be
actively involved in the maintenance of the slow-cycling state94, May 14, 2010 ª2010 Elsevier Inc. 591
in melanoma via stabilization of pRB (Ser795)-mediated cell
cycle control (Roesch et al., 2006). Interestingly, stabilization of
hypophosphorylated pRB is usually understood as a tumor-
suppressive mechanism because of its anti-proliferative effect,
but in the long run, slow proliferation can be also associated
with tumor maintenance as we suggest here. Thus, JARID1B
may have a dual role over time, immediately anti-proliferative
but long-term tumor maintaining.
JARID1B is overexpressed in breast cancer (Lu et al., 1999)
raising the question of whether it determines also in epithelial
malignancies a population with increased stemness capacity.
Our unpublished observations from head and neck squamous
cell carcinoma (HNSCC) revealed a broad JARID1B immunore-
activity throughout the entire epithelial portion and, thus, in a
pattern very different from that of melanoma. A possible expla-
nation for this discrepancy is provided by publications on
another family member, JARID2. JARID2 can be expressed in
an undulating fashion. It is strongly expressed in embryonic
stem cells, decreases when cells proliferate and tissues expand,
but increases again after terminal differentiation (Takeuchi et al.,
2006). Thus, the observed immunostaining pattern of HNSCCs
could reflect a high expression of JARID1B also in differentiated
carcinoma cells. Since epithelial carcinomas generally harbor
more differentiated cells than melanomas, it was also not
surprising that sorted label-retaining esophageal carcinoma
cells showed decreased stemness (differentiated cells were
less clonogenic, not shown). Consequently, to unravel the role
of JARID1B as a marker for epithelial CSCs, further biological
markers are needed to exclude the differentiated progeny.
According to the traditional CSC concept, tumor initiation is
regarded as an exclusive characteristic of CSCs (Clarke et al.,
2006). Thus, our finding that tumor initiation in immunodeficient
animals is independent of JARID1B expression challenges the
role of JARID1B as a classic CSC marker. In highly susceptible
xenotransplantation assays like the one we used, the ratio of
tumor initiating cells can increase up to 25% of unsorted cells
(Quintana et al., 2008). This suggests that either virtually every
melanoma cell is a CSC because it can induce de novo tumors
in xenograft assays irrespective of any known stem cell marker,
or that melanoma is not hierarchically organized into subpopula-
tions of tumorigenic and nontumorigenic cells and the CSC
model does not apply. However, tumor initiation in xenograft
models could be more dependent on secondary factors, such
as the adaptation to host-derived growth factors (Adams and
Strasser, 2008). For example, congenic transplantation of
murine lymphoma cells revealed that tumor initiation is not
necessarily restricted to a minority population (Kelly et al.,
2007). Thus, it is generally questionable whether the ability of
melanoma cells to initiate de novo tumors really reflects the
same potential as to maintain growth within an already estab-
lished tumor microenvironment. Particularly the normalized
growth data in Figure 5B support that this assay measures
more the gradual loss of tumor growth than the loss of tumor
initiation.
The Weinberg group recently observed a dependency of
self-renewal on exogenous factors. Treatment of immortal
human mammary epithelial cells with recombinant TGFb could
induce the stem like CD44high/CD24low phenotype known from592 Cell 141, 583–594, May 14, 2010 ª2010 Elsevier Inc.breast CSCs (Mani et al., 2008). Ours and Weinberg’s data
suggest that at least some stem-like cells from solid tumors
may actually not be static entities, but rather tumor cells that
transiently acquire stemness properties depending on the tumor
context. This supports a model of dynamic stemness in which at
any given point of time a slow-cycling, self-renewing but
dynamic subpopulation of tumor cells exists among the bulk
of tumor cells. This subpopulation might continually arise or
disappear (‘‘moving target’’). Certainly, improved assays, e.g.,
humanized mouse models, are critically needed to address
these questions in the future.
Since the study by Mani et al. suggested epithelial-mesen-
chymal transition (EMT) as an alternative stemness-associated
mechanism, we asked if also JARID1B-positive melanoma cells
show EMT or, at least, an EMT-like phenotype (because of their
neuroectodermal origin, melanoma cells may not undergo
classic EMT). However, none of our genome-wide profiling
experiments (1. JARID1B knockdown versus scrambled, 2. tran-
sient JARID1B overexpression versus mock, and 3. J/EGFP-
positive versus J/EGFP-negative) detected a consistent classic
EMT signature in correlation with high JARID1B expression.
We also did not find a consistent overlap with previously sug-
gested stemness markers, like CD133 (Monzani et al., 2007)
and p75/NGFR (Wong et al., 2006). A trend toward higher
expression of CD20 (Fang et al., 2005) in J/EGFP-positive cells
was assumed but due to the low overall expression frequency
of CD20 (0.7%–2%), there was a lack of experimental consis-
tency in replicate analyses (data not shown).
The existence of a slow-cycling subpopulation is of high
clinical importance because almost all current therapeutic regi-
mens predominantly target the rapidly proliferating tumor bulk
(Blagosklonny, 2005). Indeed, we observed that anti-cancer
therapies in vitro (cytotoxic or BRAFV600E-targeted) uniformly
result in an enrichment for JARID1B-positive cells (data not
shown). Thus, we postulate that targeting of the slow-cycling
subpopulation, e.g., by inhibition of its H3K4 demethylase
activity, in combination with a conventional debulking strategy
could help eradicate all melanoma cells and increase the low
therapy response rate in malignant melanoma.EXPERIMENTAL PROCEDURES
Melanoma Samples, Cell Lines, and Lentiviral Constructs
Human melanoma tissues and cell lines were obtained in accordance with
consent procedures approved by the Internal Review Boards of the University
of Pennsylvania School of Medicine, The Wistar Institute, and the Regensburg
University Medical Center (see also Extended Experimental Procedures). Cells
were isolated and maintained in 2% FBS-substituted melanoma medium
(Tu2%) as previously described (Satyamoorthy et al., 1997). Melanoma
spheres were propagated in mouse embryonic fibroblast (MEF)-conditioned
human embryonic stem cell medium as reported (hESCM4, Fang et al.,
2005). Spheres were dissociated by collagenase I/IV (Sigma) and mechanical
treatment, i.e., 200–250 units per ml DMEM (Cellgro) at 37C for 10 min plus
subsequent pipetting. Cell viability was assured microscopically and by
7-AAD dead cell exclusion as explained in Extended Experimental Proce-
dures. The consistency of cellular genotypes was confirmed by DNA finger-
printing using Coriell’s microsatellite kit. The lentiviral vector constructs for
stable knockdown of JARID1B and the scrambled control were purchased
from Sigma. Lentiviral pLU-CMV-Blast and pLU-CMV-EGFP (Wistar Libraries
Core Facility) were used to clone pLU-JARID1Bprom-EGFP-Blast and
pLU-CMV-EGFP-Blast. The JARID1B main promoter was PCR-cloned from
human genomic DNA (Promega) and verified by DNA sequencing as described
in Extended Experimental Procedures. Selection of positive clones was done
by treatment with puromycin or blasticidin.
Detection of JARID1B
JARID1B-immunohistochemistry and -immunofluorescence microscopy were
done with a polyclonal rabbit anti-JARID1B antibody (Roesch at al., 2005). For
immunoblotting, we used anti-JARID1B aa 784-883 No. 2226.00.02 from Stra-
tegic Diagnostics. Quantitative real time RT-PCR was done in an ABI PRISM
7000 using own primers or primers from the Harvard primer bank http://pga.
mgh.harvard.edu/primerbank (see also Extended Experimental Procedures).
Flow Cytometry and FACS of J/EGFP Signals
For detection of JARID1B promoter-driven EGFP signals, adherent
WM3734JARID1Bprom-EGFP cells were harvested with 0.05% trypsin and spheres
were dissociated as described before. Dead cells were excluded by staining
for 7-AAD. All experiments were performed by the Wistar Flow Cytometry
Facility using an EPICS XL instrument (Beckman-Coulter) and a Cytomation
MoFlo cytometer (DakoCytomation). After sorting, aliquots were microscopi-
cally checked and were cultured for a short time to exclude disproportional
enrichment of debris or apoptotic cells.
Cell Proliferation and Colony-Formation Assays
Cell proliferation was quantified by MTS (Promega) and BrdU incorporation
assays (Roche) according to the manufacturers’ protocols and confirmed by
manual cell counts using a hematocytometer. Anchorage-independent colony
formation was measured in 0.35% soft agar assays (see also Extended
Experimental Procedures).
In Vitro Self-Renewal Assay
Quantitation of melanoma sphere self-renewal was done by limited (single cell)
dilution assays. Briefly, cells were seeded at a ratio of 0.5 cell per well in
96-well plates to avoid doublets. Using an Olympus CKX41SF phase contrast
microscope, wells containing one live cell were marked after 2 hr. Develop-
ment of spheres was assessed after 20–30 days.
In Vivo Self-Renewal and Metastasis Assays
All animal experiments were performed in accordance with Wistar IACUC
protocol 111983 in NOD/LtSscidIL2Rgnull mice. Titrated xenotransplantation
of J/EGFP-sorted cells was done for 100, 10, and 1 cell per injection (5 mice
per sample, 4 injections per mouse). 100 and 10 cell dilutions were based on
FACS counts and were verified microscopically. Preparation of single cell
injections was performed as published elsewhere (Quintana et al., 2008). For
serial xenotransplantation, 104 cells were subcutaneously injected at a Matri-
gel/Tu2% ratio of 1:1 (5 mice per sample). One passage comprised: injection,
tumor growth, tumor dissection, cell isolation (mechanical and collagenase I/IV
treatment) and melanoma cell purification (3 day puromycin treatment
confirmed by melanoma-specific MCAM flow cytometry). Verification of
knockdown was done by QPCR before reinjection and immunohistochemistry
of tumor sections. Tumor growth was measured weekly using a caliper and
was terminated when the first tumor of the series reached 1000mm. For induc-
tion of spontaneous pulmonary metastasis, 53 105WM3899 JARID1B knock-
down melanoma cells were injected subcutaneously (5 mice per sample) and
incubated for 5 weeks. Metastases were microscopically determined as
described in Extended Experimental Procedures.
In Vitro and In Vivo Label-Retaining Assays
In vitro label-retaining (LR) of cells was done using the PKH26 Red Fluorescent
Cell Linker Kit for general membrane labeling (Sigma). 100% labeling
efficiency was reached with 106 dissociated sphere cells incubated in 100 ml
of 1 mM PKH26. LR was determined by flow cytometry and fluorescence
microscopy. For in vivo BrdU-LR, 104 cells were xenotransplanted into
NOD/LtSscidIL2Rgnull mice (n = 10). Five of the mice were given a single i.p.
injection of 1.5 mg BrdU in DPBS and were subsequently maintained on
1 mg/ml BrdU in the drinking water for 12 days. Five mice served as controls.Tumors were grown for an additional 6 weeks. BD PharMingen’s APC BrdU
Flow Kit was used for detection.
Statistics
To determine the statistical significance of growth curves, ANOVA for repeated
measures was applied and, when significant, group differences were evalu-
ated using a Student’s t-test. Differences in limited dilution assays were statis-
tically determined using Fisher’s Exact Test. For all other experiments, the
Student’s t test was used. A p value of less than 0.05 was considered sig-
nificant. As software tools, SAS version 9.2 using Proc Freq and Microsoft
Excel were used.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures,
Supplemental References, and six figures and can be found with this article
online at doi:10.1016/j.cell.2010.04.020.
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